



July 27, 2026
Pfizer Japan Inc.
Eisai Co., Ltd.

Pfizer and Eisai Commence Co-promotion of “NURTEC®” for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

Pfizer Japan Inc. (Headquarters: Tokyo, President and Representative Director: Hiroo Igarashi, “Pfizer”) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the companies will commence the co-promotion of the oral calcitonin gene-related peptide (CGRP) receptor antagonist Nurtec® OD Tablet 75mg (generic name: rimegepant sulfate hydrate, hereinafter “Nurtec”) in Japan from September 1, 2026.

Nurtec is an oral CGRP receptor antagonist, indicated for both acute treatment and prophylaxis of migraine.

This co-promotion aims to facilitate the timely and broad dissemination of information on the appropriate use of Nurtec in the treatment of migraine. Both companies will provide appropriate use information to medical institutions in Japan, while Pfizer remains responsible for the development, manufacturing, distribution, and commercialization of Nurtec.

Through this collaboration, Pfizer, the marketing authorization holder, and Eisai, which positions neurology as a strategic focus area, will leverage their respective expertise and healthcare networks to further strengthen the provision of information and promote the appropriate use of Nurtec.

Migraine is a debilitating neurological disorder that can significantly impair daily life due to headaches and accompanying symptoms during attacks, and there remain many patients whose conditions are not adequately controlled. Through this initiative, Pfizer and Eisai aim to help patients suffering from the disorder to regain their everyday lives by promoting the widespread adoption of appropriate treatment options.

Nurtec Product Outline

Product Name	Nurtec OD Tablet 75mg
Generic name	Rimegepant Sulfate Hydrate
Indications and Usage	Acute treatment and prophylaxis of migraine attacks
Dosage and Administration	Acute treatment of migraine attacks For adults, the recommended dose is 75mg rimegepant, as needed, once daily. Prophylaxis of migraine For adults, the recommended dose is 75mg rimegepant every other day
Approval Date	September 19, 2025
Launch Date	December 16, 2025
Manufactured and Marketed by:	Pfizer Japan Inc.

About Rimegepant

About Migraine

References

- * * * * *

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at [@Pfizer](https://twitter.com/Pfizer) and [@Pfizer](https://www.youtube.com/Pfizer) News, [YouTube](https://www.youtube.com/Pfizer) and like us on Facebook at [Facebook.com/Pfizer](https://www.facebook.com/Pfizer).

Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as *human health care (hhc)* Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.

For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on [X](#), [LinkedIn](#) and [Facebook](#).

Media Inquiries:

Pfizer Japan Inc. Corporate Communications
JPN-ExtComms_inquiry1@pfizer.com

Eisai Co., Ltd. Public Relations Department
+81-(0)3-3817-5120

#####